ATE245993T1 - Allosterische modulatoren des nmda-rezeptors - Google Patents

Allosterische modulatoren des nmda-rezeptors

Info

Publication number
ATE245993T1
ATE245993T1 AT95936300T AT95936300T ATE245993T1 AT E245993 T1 ATE245993 T1 AT E245993T1 AT 95936300 T AT95936300 T AT 95936300T AT 95936300 T AT95936300 T AT 95936300T AT E245993 T1 ATE245993 T1 AT E245993T1
Authority
AT
Austria
Prior art keywords
nmda receptor
allosteric modulators
compositions
methods
receptor function
Prior art date
Application number
AT95936300T
Other languages
English (en)
Inventor
Maria-Luisa Maccecchini
Original Assignee
Bearsden Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/323,436 external-priority patent/US5830998A/en
Application filed by Bearsden Bio Inc filed Critical Bearsden Bio Inc
Application granted granted Critical
Publication of ATE245993T1 publication Critical patent/ATE245993T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Liquid Crystal Substances (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT95936300T 1994-10-14 1995-10-13 Allosterische modulatoren des nmda-rezeptors ATE245993T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/323,436 US5830998A (en) 1992-09-28 1994-10-14 Allosteric modulators of the NMDA receptor and their use in the treatment of CNS disorders and enhancement of CNS function
US08/413,490 US5854217A (en) 1992-09-28 1995-03-30 Allosteric modulators of the NMDA receptor and their use in the treatment of CNS disorders and enhancement of CNS function
PCT/US1995/013037 WO1996011698A1 (en) 1994-10-14 1995-10-13 Allosteric modulators of the nmda receptor

Publications (1)

Publication Number Publication Date
ATE245993T1 true ATE245993T1 (de) 2003-08-15

Family

ID=26983959

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95936300T ATE245993T1 (de) 1994-10-14 1995-10-13 Allosterische modulatoren des nmda-rezeptors

Country Status (7)

Country Link
US (5) US5854217A (de)
EP (1) EP0785793B1 (de)
JP (1) JP3273792B2 (de)
AT (1) ATE245993T1 (de)
CA (1) CA2202513C (de)
DE (1) DE69531403D1 (de)
WO (1) WO1996011698A1 (de)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5854217A (en) 1992-09-28 1998-12-29 Bearsden Bio, Inc. Allosteric modulators of the NMDA receptor and their use in the treatment of CNS disorders and enhancement of CNS function
US5763393A (en) * 1996-05-17 1998-06-09 Neurotherapeutics L.P. Neuroactive peptides
AU735389B2 (en) 1996-07-22 2001-07-05 Cognetix, Inc. Use of conantokins
US6277825B1 (en) 1996-07-22 2001-08-21 University Of Utah Research Foundation Use of conantokins for treating pain
EP0956292A4 (de) * 1996-07-22 2003-07-30 Univ Utah Res Found Conantokine
WO1998036743A1 (en) * 1997-02-21 1998-08-27 Cypros Pharmaceutical Corporation Neuroprotective poly-guanidino compounds which block presynaptic n and p/q calcium channels
US5844077A (en) * 1997-04-28 1998-12-01 Cytotherapeutics, Inc. Use of conantokins for producing analgesia or for neuroprotection
EP1057023A1 (de) * 1998-02-10 2000-12-06 University of Utah Research Foundation Verfahren zur reinigung und bestimmung einer conus-spezifischen v-carboxylase
EP1214335A4 (de) * 1999-09-10 2003-04-23 Univ Utah Res Found Gamma-carboxyglutamat enhaltende conopeptide
US6399574B1 (en) 2000-03-22 2002-06-04 University Of Utah Research Foundation Use of conantokins
AU8676301A (en) * 2000-08-25 2002-03-04 Res Corp Technologies Inc New uses for amino acid anticonvulsants
AU2002248553A1 (en) * 2001-03-07 2002-09-24 Cognetix, Inc Linear y-carboxyglutamate rich conotoxins
CA2442330A1 (en) * 2001-03-29 2002-10-10 Emory University Acute pharmacologic augmentation of psychotherapy with enhancers of learning or conditioning
US20070197583A1 (en) * 2002-03-29 2007-08-23 Welsh Michael J Novel compositions and methods for modulation of the acid-sensing ion channel (ASIC) for the treatment of anxiety and drug addiction
US20030186860A1 (en) * 2002-03-29 2003-10-02 Welsh Michael J. Novel compositions and methods for modulating the acid-sensing ion channel (ASIC)
US7273889B2 (en) * 2002-09-25 2007-09-25 Innovative Drug Delivery Systems, Inc. NMDA receptor antagonist formulation with reduced neurotoxicity
AU2002952993A0 (en) 2002-11-29 2002-12-12 The Corporation Of The Trustees Of The Order Of The Sisters Of Mercy In Queensland Therapeutic and diagnostic agents
AU2003901325A0 (en) 2003-03-21 2003-04-03 Stephen Locarnini Therapeutic, prophylactic and diagnostic agents
EP1667516A4 (de) 2003-08-29 2009-11-11 Inst Medical W & E Hall Verfahren zur auswahl von tiermodellen von tieren, die mutagenese unterzogen worden sind, und verwendung von myb-transkriptionsfaktoren zum screening
US7176185B2 (en) * 2003-11-25 2007-02-13 Tsrl, Inc. Short peptide carrier system for cellular delivery of agent
EP1701736A4 (de) 2003-12-24 2008-05-07 Inst Medical W & E Hall Therapeutische mittel und ihre verwendungen
WO2005108981A1 (en) 2004-05-12 2005-11-17 The Walter And Eliza Hall Institute Of Medical Research A method of cell isolation
AU2006261599B2 (en) 2005-06-24 2011-10-06 The Walter & Eliza Hall Institute Of Medical Research Therapeutic pro-apoptotic BH3-like molecules and methods for generating and/or selecting the same
CN100341566C (zh) * 2005-12-29 2007-10-10 中国人民解放军军事医学科学院生物工程研究所 芋螺多肽衍生物用于制备戒毒药物的用途
WO2007082352A1 (en) 2006-01-20 2007-07-26 Child Health Research Institute Inc Method of treatment, prophylaxis and diagnosis of pathologies of the bone
AU2007275764B2 (en) 2006-07-18 2013-11-14 University Of Utah Research Foundation Methods for treating pain and screening analgesic compounds
US20090291150A1 (en) * 2008-05-21 2009-11-26 University Of Iowa Research Foundation Method and compositions for treating and preventing seizures by modulating acid-sensing ion channel activity
BRPI0902039B8 (pt) 2009-06-09 2021-05-25 Anhanguera Educacional Ltda composição farmacêutica e uso de composição farmacêutica para o tratamento, profilaxia ou prevenção de doenças neoplásicas em humanos e animais
EP2260864A1 (de) 2009-06-10 2010-12-15 University of Melbourne Therapeutische Anwendungen
CA2803029A1 (en) 2010-06-23 2011-12-29 Monash University Constrained immunogenic compositions and uses therefor
CN103354748B (zh) 2010-08-04 2016-09-28 麦克法兰博尼特医学健康研究公司 修饰的丙型肝炎病毒蛋白
CN104324373B (zh) 2010-11-26 2018-10-09 麦克法兰博尼特医学健康研究公司 组合物及其制备方法
JP6681826B2 (ja) 2013-05-31 2020-04-15 ザ ユニバーシティ オブ ユタ リサーチ ファウンデイション コノトキシンペプチド、医薬組成物およびそれらの使用
US10647679B2 (en) 2015-03-15 2020-05-12 Emory University N-methyl-D-aspartate receptor (NMDAR) potentiators, pharmaceutical compositions, and uses related thereto
US10111554B2 (en) 2015-03-20 2018-10-30 Meltz, LLC Systems for and methods of controlled liquid food or beverage product creation
US10314320B2 (en) 2015-03-20 2019-06-11 Meltz, LLC Systems for controlled liquid food or beverage product creation
JP6877419B2 (ja) 2015-10-27 2021-05-26 ザ ユニバーシティー オブ クイーンズランド 治療の方法およびそのために有用な剤
WO2017109756A2 (es) * 2015-12-22 2017-06-29 Universidad Nacional De Colombia Péptidos sintéticos moduladores del receptor nmda
EP3526230A4 (de) 2016-10-12 2020-11-25 Glycosynnovations Pty Ltd Therapeutika und verfahren zur herstellung davon
AU2017344755B2 (en) * 2016-10-20 2023-02-02 Memphasys Limited Electrophoresis device
CA3061607A1 (en) 2017-04-27 2018-11-01 Meltz, LLC Method for centrifugal extraction and apparatus suitable for carrying out this method
US11724849B2 (en) 2019-06-07 2023-08-15 Cometeer, Inc. Packaging and method for single serve beverage product
EP4085066A4 (de) * 2020-01-05 2023-09-27 Technion Research & Development Foundation Limited Conus-basierte toxin-peptide, dafür codierende nukleinsäuren und verwendungen davon zum modulieren von nmda-rezeptoren
JP2023511370A (ja) 2020-01-22 2023-03-17 シーロス セラピューティクス， インコーポレイテッド Ｎｍｄａ拮抗薬の副作用の低減

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5051413A (en) 1986-02-13 1991-09-24 Ciba-Geigy Corporation Unsaturated amino acids
US4806543A (en) 1986-11-25 1989-02-21 Board Of Trustees Of The Leland Stanford Junior University Method and compositions for reducing neurotoxic injury
CA1305177C (en) 1987-06-30 1992-07-14 Yasufumi Ohfune Carboxycyclopropylglycine and process for producing the same
US5049555A (en) 1988-12-19 1991-09-17 Nova Pharmaceutical Corporation Antagonists of specific excitatory amino acid receptors as neuroprotectants and anxiolytics
US5061721A (en) * 1989-03-15 1991-10-29 G. D. Searle & Co. Composition containing d-cycloserine and d-alanine for memory and learning enhancement or treatment of a cognitive or psychotic disorder
US6017957A (en) * 1989-08-08 2000-01-25 The United States Of America As Represented By The Department Of Health And Human Services Partial agonists of the strychnine insensitive glycine modulatory site of the N-methyl-D-aspartate receptor complex as neuropsychopharmacological agents
US5559095A (en) * 1989-11-22 1996-09-24 Neurex Corporation Delayed treatment method of reducing ischemia-related neuronal damage
US5051403A (en) * 1989-11-22 1991-09-24 Neurex Corporation Method of treating ischemia-related neuronal damage
US5086072A (en) * 1990-06-18 1992-02-04 The United States Of America As Represented By The Department Of Health And Human Services Treatment of mood disorders with functional antagonists of the glycine/nmda receptor complex
GB9109007D0 (en) 1991-04-26 1991-06-12 Merck Sharp & Dohme Therapeutic method
CA2115442C (en) 1991-09-09 2003-09-23 Christopher Franklin Bigge Pharmaceutical preparation containing an uricosuric agent and an excitatory amino acid antagonist
US5854217A (en) 1992-09-28 1998-12-29 Bearsden Bio, Inc. Allosteric modulators of the NMDA receptor and their use in the treatment of CNS disorders and enhancement of CNS function
JPH07505908A (ja) * 1992-09-28 1995-06-29 マックセチーニ、マリア　ルイザ Ｎｍｄａ受容体のアロステリックモジュレーター
US5428069A (en) 1993-01-11 1995-06-27 The United States Of America As Represented By The Department Of Health & Human Services Treating cognition with, aminocyclopropanecarboxylic derivatives
US5432155A (en) 1993-06-29 1995-07-11 The Salk Institute For Biological Studies Conotoxins I
US5523323A (en) * 1993-09-14 1996-06-04 Maccecchini; Maria-Luisa Use of partial agonists of the NMDA receptor to reduce opiate induced tolerance and dependence
DE19543478A1 (de) * 1995-11-22 1997-05-28 Bayer Ag Kristallines Hydrochlorid von {(R)-(-)-2- N-[4-(1,1-Dioxido-3-oxo-2,3-dihydrobenzisothiazol-2-yl)-buytl]-aminomethyl}-chroman
AU735389B2 (en) * 1996-07-22 2001-07-05 Cognetix, Inc. Use of conantokins
US5844077A (en) * 1997-04-28 1998-12-01 Cytotherapeutics, Inc. Use of conantokins for producing analgesia or for neuroprotection

Also Published As

Publication number Publication date
US6110894A (en) 2000-08-29
CA2202513A1 (en) 1996-04-25
US5854217A (en) 1998-12-29
EP0785793B1 (de) 2003-07-30
US6511963B1 (en) 2003-01-28
US6284731B1 (en) 2001-09-04
JPH10504316A (ja) 1998-04-28
DE69531403D1 (de) 2003-09-04
EP0785793A4 (de) 2000-08-30
EP0785793A1 (de) 1997-07-30
US20030134799A1 (en) 2003-07-17
JP3273792B2 (ja) 2002-04-15
CA2202513C (en) 2002-08-13
WO1996011698A1 (en) 1996-04-25

Similar Documents

Publication Publication Date Title
DE69531403D1 (de) Allosterische modulatoren des nmda-rezeptors
NO986100D0 (no) Androgene reseptormodulerende forbindelser og fremgangsmÕter
BR9510486A (pt) Compostos moduladores de receptores de esteróide e métodos
MY141384A (en) Prevention of loss and restoration of bone mass by certain prostaglandin agonists
EP0911321A3 (de) Verbindungen zur Behandlung von Osteoporose
MY129189A (en) Prostaglandin agonists and their use to treat bone disorders
MX9704640A (es) Compuesto moduladores de los receptores de los esteroides y metodos para su preparacion.
FI20051271L (fi) Yhdisteet ja koostumukset GABA-reseptorin allosteeriseksi moduloimiseksi
AP9801269A0 (en) Prostaglandin agonists.
DK0841928T3 (da) Sustained release-formulering af d-threo-methylphenidat
YU7797A (sh) Kombinovana terapija za osteoporozu
AU2002345497A1 (en) Cips as modifiers of the p53 pathway and method of use
GB9712966D0 (en) Novel chalcones
BR9708347A (pt) Compostos de tetrahidorbeta-carbonila
DE69808475D1 (de) Aminosäurederivate zur behandlung von schlaganfall
BR9714189A (pt) N-(piridinilamino) isoindolinas e compostos relacionados
ID27964A (id) Turuna-azabisikloheptana n-tersubstitusi, pembuatan dan penggunaannya

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties